aTyr Pharma Inc. (ATYR)
ATYR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.2011
-6.38% on the day
Market cap
$19.7M
Nano cap
Revenue · 2025
$190K
-19.1% on 2024
Net income · 2025
-$74.1M
-39009.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ATYR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001339970 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $190K |
| Net income | -$74.1M |
| Operating income | -$77.6M |
| Net margin | -39009.5% |
| Operating margin | -40856.3% |
| Revenue growth | -19.1% |
| Cash | $10.7M |
| Total assets | $93.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 103.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-08-07 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-08-07 |
| Latest current report | 8-K | 2026-09-24 |
| Latest proxy | DEF 14A | 2026-09-11 |
Source: SEC EDGAR submissions feed, 748 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DYAI | Dyadic International Inc. | $0.4253 | +1.00% | $17.0M |
| JSPR | Jasper Therapeutics Inc. | $0.4956 | -10.70% | $16.5M |
| EVAX | Evaxion A/S American Depositary Share | $2.76 | -8.00% | $24.9M |
| BCDA | BioCardia Inc. | $0.9903 | -2.91% | $15.0M |
| TCRX | TScan Therapeutics Inc. | $0.2167 | -8.91% | $13.8M |
| ESLA | Estrella Immunopharma Inc. | $0.3140 | -4.44% | $13.7M |
| CVM | Cel-Sci Corporation | $1.75 | -4.37% | $30.8M |
| PLUR | Pluri Inc. | $0.9400 | -3.08% | $11.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier